All articles tagged with #eli lilly
STAT reports that the Trump administration’s GLP-1 price plan—$245 a month for Medicare/Medicaid, tied to insurer coverage for all uses with a $50 copay—did not consistently lower prices and instead boosted sales volume for Eli Lilly and Novo Nordisk in some cases.
The FDA has chosen seven companies, including Eli Lilly and Regeneron, to join a PreCheck pilot that lets regulators begin reviewing new manufacturing facilities while they’re under construction, with the goal of catching issues early and potentially shaving up to 14 months from timelines. The program comprises facility readiness guidance and an expedited application submission/inspection process, and targets drugs produced domestically—especially biologics and gene therapies.
Healthcare stocks outperformed the broader market as Eli Lilly (LLY), Johnson & Johnson (JNJ) and AbbVie (ABBV) hit fresh 52-week highs (with Merck near highs), while biotech names like Moderna led rallies; the Health Care Select Sector SPDR ETF XLV has climbed about 3% year-to-date, signaling renewed investor interest in defensive healthcare plays amid ongoing M&A activity.
Eli Lilly CEO David Ricks says GLP-1 drugs could be more transformative than AI, with strong weight‑loss and health benefits that could curb the roughly $1.4 trillion annual obesity‑related healthcare costs. He notes pricing moves and upcoming Medicare access (around $50 a month starting July) could broaden adoption, while Lilly’s tirzepatide program underscores how GLP‑1 therapies might reshape U.S. healthcare and chronic disease management.
STAT reports that Eli Lilly and the FDA approved compassionate-use access for retatrutide, an experimental obesity drug, to a 79-year-old man—a move that drew attention from top health officials and highlighted concerns about access to promising therapies before FDA approval.
Drugmakers are racing to improve GLP-1 weight‑loss drugs, aiming to reduce the burden of weekly injections and gastrointestinal side effects while preserving muscle and bone health, led by Eli Lilly and Novo Nordisk.
The Readout highlights Eli Lilly’s two China deals, Akeso’s promising lung cancer bispecific, and ASCO-driven updates on pancreatic cancer therapies (including daraxonrasib results), alongside chatter about a high-profile Chinese lung cancer therapy and a broader regulatory debate over an old peptide, illustrating how deals, trials, and policy are shaping biotech today.
A man on retatrutide, an experimental GLP-1 weight-loss drug from Eli Lilly, posts dramatic before-and-after photos claiming about 85 pounds lost over two years; the drug is still in development and not yet available in the UK, though GLP-1 therapies are used for weight loss in the NHS under certain conditions; the posts emphasize health and longevity over appearance.
Eli Lilly’s experimental GLP-1 drug retatrutide produced an average 28% weight loss in obese patients, a striking boost over existing GLP-1 therapies, but doctors warn that greater potency can bring new safety risks; the company expects to file for FDA approval by 2026.
Eli Lilly said it will buy Curevo, LimmaTech Biologics and The Vaccine Company for almost $4 billion in cash to expand infectious-disease R&D, sending its shares higher in premarket trading. Curevo develops a shingles vaccine, LimmaTech targets resistant bacterial pathogens including STIs, and The Vaccine Company advances in vivo nanoparticle delivery technologies for drugs, genes, and diagnostics. The move comes as Lilly relies on Zepbound and Mounjaro for strong revenue and introduces Foundayo to compete with Novo Nordisk in obesity treatments.
Eli Lilly’s high-dose, one-time gene-editing therapy VERVE-102 lowered LDL cholesterol by 62% in a Phase 1 trial, with no treatment-related serious adverse events, signaling potential for a single-shot approach to prevent heart disease after Lilly’s $1 billion acquisition of Verve Therapeutics.
New observational studies suggest GLP-1 weight-loss drugs like Ozempic and Mounjaro may slow cancer progression, lower recurrence, and improve breast-cancer survival, a finding that could bolster Novo Nordisk and Eli Lilly’s valuations as leaders in obesity/diabetes therapies.
Phase 3 data show Lilly’s investigational triple-hormone drug retatrutide delivering up to 28.3% average weight loss over 80 weeks at the highest dose (vs. 2.2% placebo), with about 45% of patients achieving 30%+ loss and even greater reductions in those with BMI ≥35. A lower 4 mg dose yielded 19% weight loss with better tolerability. Common side effects were GI (nausea, diarrhea, constipation); no major cardiac or liver issues were observed. If results hold, Lilly could file for approval, potentially solidifying retatrutide as a top player in a booming obesity market, ahead of Novo Nordisk’s competing therapies.
Pharma is racing to commercialize next-generation obesity drugs as pivotal readouts approach from Lilly, Viking Therapeutics, and Pfizer; Lilly’s retatrutide shows potentially stronger weight loss and knee-pain relief in Triumph-4, Viking is testing maintenance dosing for VK2735, and Pfizer’s PF’3944 posted encouraging phase 2b results for monthly maintenance injections, signaling a crowded path to a multi-billion GLP-1 market by 2030.
Novo Nordisk’s Wegovy oral pill has gained strong early momentum since its January launch, aided by aggressive marketing and a lower monthly price, while Lilly’s Foundayo is ramping up more slowly. Telehealth platforms report rapid uptake for Wegovy, and investors are watching first-quarter results and potential international expansion as the GLP-1 pill market expands beyond injections.